Randomized Trialhigh evidence
Heterogeneity of microbiome responses to menopausal hormone therapy among perimenopausal women.
Nature medicine·November 3, 2026·PMID 42977757
Why it mattersMenopausal hormone therapy response varies widely; this trial identifies baseline microbiome signatures that predict clinical and sexual function improvements, offering a potential precision-medicine approach to personalize MHT for perimenopausal women.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled